ReviewHematology. American Society of Hematology. Education Program2022

The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies.

Lauren Pommert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.